Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05653752 | A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer | PHASE1 | ACTIVE NOT_RECRUITING | 80 | — | — | Dec 20, 2022 | Dec 1, 2026 | May 15, 2026 | 13 | United States, China |
| Arm | Type | Description |
|---|---|---|
| YL202 Dose escalation | EXPERIMENTAL | YL202 will be administrated intravenously (IV) per dose level in which the patients are assigned. |
| Name | Type | Description |
|---|---|---|
| YL202 | DRUG | YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle. The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes. |
Inclusion Criteria Patients must satisfy all of the following criteria to be included in the study: 1. Informed of the trial before the start of the trial and voluntarily sign their name and date on the informed consent form 2. Aged ≥18 years 3. Eastern Cooperative Oncology Group performance statu...